United Therapeutics(NASDAQ) UTHR

United Therapeutics makes medicines for people with rare and severe lung diseases. The company helps patients breathe better by opening up blood vessels and reducing lung damage. It also works on high-tech ways to create new organs for people who need transplants.

Helping Patients Breathe

• Tyvaso DPI and Nebulized Tyvaso: Inhaled medicines for lung high blood pressure and scarring; accounts for 59% of revenue in 2025.
• Remodulin: Injection therapy delivered by a small pump for patients with severe lung artery pressure; represents 17% of revenue in 2025.
• Orenitram: Tablet version of the company's main lung medicine used to delay disease worsening; represents 16% of revenue in 2025.
• Unituxin: Specialized treatment for high-risk neuroblastoma, which is a rare cancer found in children; accounts for 7% of revenue in 2025.
• Adcirca: Once-daily pill used to improve the ability to exercise in patients with lung high blood pressure; accounts for 1% of revenue in 2025.

Expanding the Pipeline

• Acquired Miromatrix Medical Inc. in December 2023 to develop new ways to grow manufactured kidneys and liver alternatives.
• Purchased IVIVA Medical, Inc. in October 2023 to focus on creating bio-artificial kidney products that work without the need for anti-rejection drugs.
• Partnered with MannKind Corporation to develop and license a dry powder version of inhaled medicine using specialized device technology.
• Collaborated with BETA Technologies, Inc. to develop electric aircraft meant to deliver manufactured organs with zero carbon emissions.

What Makes the Company Unique

United Therapeutics is a public benefit corporation, meaning its legal charter requires it to help patients and society alongside making profits. The company operates its own manufacturing facilities to produce complex medicines and is a leader in using 3D printing to create lung scaffolds.

Key Financial Facts

• Revenue reached $790.2 million in Q4 2025, up 7.4% from the previous year.
• Net income rose to $364.3 million in Q4 2025, a 20.9% increase year-over-year.
• Market capitalization grew to $21.6 billion in Q4 2025, up 35.3% from Q4 2024.
• Operating cash flow was $346.2 million in Q4 2025, up 1.5% from the prior year.
• Free cash flow was $173.3 million in Q4 2025, down 31.9% year-over-year due to capital spending.

Bottom Line

United Therapeutics has transitioned from a pure drug developer into a biotechnology firm focused on both rare disease therapies and organ manufacturing. This dual focus supports long-term growth by addressing severe medical needs through pharmaceutical and engineering solutions.